Developer docs
API playgroundTry for free, no card

Search company profiles

TISSIUM

Full company profile

uuid000237b

Namestring
TISSIUM
Legal namestring
Tissium SA
Websiteurl
tissium.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

TISSIUM (formerly Gecko Biomedical) is a Paris-headquartered, privately-held medtech company founded in 2013 that develops proprietary biomorphic programmable polymers for tissue reconstruction. The company's core technology is a family of fully biosynthetic, light-activated polymers that conform to and integrate with surrounding tissue and whose building blocks can be tuned to match tissue-specific mechanical and biological requirements; these polymers are deployed alongside 3D-printed bioresorbable chambers using proprietary digital light projection manufacturing techniques. The IP base derives from research at MIT and Brigham and Women's Hospital, and is protected by 26 patent families encompassing 88 granted patents.

TISSIUM monetizes its platform through the sale of medical devices to hospitals and surgical centers, with its first commercial product, COAPTIUM CONNECT — a sutureless peripheral nerve repair system — receiving FDA De Novo authorization in June 2025 and entering U.S. direct sales in July 2025. The company pursues an enterprise field-sales motion targeting surgical specialties, and is investing in additional pipeline indications including atraumatic hernia mesh fixation (first patients treated September 2023) and a CE-Marked vascular sealant (SETALIUM). TISSIUM operates a manufacturing facility in Roncq, France, a U.S. commercial office in Cambridge, Massachusetts, and is led by co-founder-CEO Christophe Bancel alongside co-founder Maria Pereira (Deputy CEO and CIO), with scientific co-founders Robert Langer (MIT) and Jeffrey M. Karp (Brigham and Women's Hospital) anchoring the research and clinical agenda.

The business has been funded through approximately €170 million of cumulative equity, debt, and non-dilutive capital from investors including Sofinnova Partners, Cathay Health, Omnes Capital, Bpifrance, the European Investment Bank, and others, including a €60 million package in 2025-2026 (a €30M Series D2 round plus a €30M EIB facility) earmarked for U.S. commercial launch and pipeline advancement. Revenue figures are not publicly disclosed, and the company is effectively at the very start of its commercial ramp following U.S. market entry.

Short descriptiontext

TISSIUM is a Paris-based medtech company developing proprietary light-activated biomorphic programmable polymers for tissue reconstruction, commercializing the FDA-authorized COAPTIUM CONNECT sutureless nerve repair system to hospitals and surgical centers while building a pipeline across hernia and cardiovascular indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomorphic programmable polymers, surgical sealants adhesives, sutureless nerve repair, tissue reconstruction devices, minimally invasive surgery
Industry1 code
PRIMARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Surgical Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Sale of medical devices for tissue reconstruction including COAPTIUM CONNECT nerve repair products and pipeline products for hernia repair and cardiovascular sealing.

tissium.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1COAPTIUM CONNECT
Description

FDA-authorized sutureless peripheral nerve repair system using biomorphic programmable polymers

tissium.com
+2 more records
Core offering1 text field

TISSIUM develops and manufactures proprietary biomorphic programmable polymers used as surgical sealants and adhesives for tissue reconstruction in open and minimally invasive procedures. Its lead commercial product, COAPTIUM® CONNECT, is an FDA-authorized sutureless peripheral nerve repair system that combines a light-activated polymer with a bioresorbable 3D-printed biopolymer chamber to coapt severed nerve endings without sutures. The polymer platform is also being applied to pipeline products for atraumatic hernia mesh fixation and vascular sealing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Enhanced reinnervation and increased muscle weight in animal studies with sutureless nerve repair system
+1 more record
Product overview1 text field

TISSIUM offers a biopolymer platform with multiple product lines. The core platform consists of proprietary biomorphic programmable polymers that conform to and integrate with surrounding tissue. The flagship commercial product is COAPTIUM® CONNECT, the first FDA-authorized sutureless nerve repair system. The product portfolio includes COAPTIUM® Nerve Products for peripheral nerve repair, hernia repair products using atraumatic fixation technology, and cardiovascular sealant products including SETALIUM™ Vascular Sealant. The platform supports multiple therapeutic areas (peripheral nerve, cardiovascular, gastrointestinal) with delivery and activation devices for enhanced performance.

Product and service3 records
1COAPTIUM® CONNECT
CategoryPeripheral nerve repair medical device
Description

First and only FDA-authorized system for atraumatic sutureless nerve coaptation, using a light-activated surgical polymer within a bioresorbable 3D-printed biopolymer chamber to join severed peripheral nerve endings without sutures. Commercially available in the United States and intended for hospitals and surgical centers performing peripheral nerve repair.

2COAPTIUM® Nerve Products
CategoryPeripheral nerve repair medical device line
Description

Product line for peripheral nerve repair, including the COAPTIUM® CONNECT sutureless nerve coaptation system and 3D-printed biopolymer nerve chambers used in atraumatic nerve repair procedures. Targeted at hand, peripheral nerve, plastic, and trauma surgeons in hospitals and surgical centers.

3SETALIUM™ Vascular Sealant
CategoryVascular sealant medical device
Description

Sterile, biodegradable, bioresorbable sealant in a pre-filled syringe for vascular reconstruction and hemostasis during peripheral vascular surgery. CE Marked for the European market and under FDA IDE in the United States; intended as a complement to sutures for effective surgical closure and prevention of post-operative bleeding.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-09-24
Description

Clinical collaboration with surgeons from NYU Langone for research on sutureless nerve repair system.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-24
Description

Co-founder Robert Langer and Jeffrey Karp from Brigham & Women's Hospital; ongoing clinical collaboration on nerve repair research.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-09-24
Description

Collaboration with surgeons from SUNY Downstate for research on sutureless nerve repair.

Strategic tierCoreTypeOthersAnnounced on2020-04-02
Description

Designated notified body under European MDR that provided ISO 13485:2016 compliance certification and CE mark for vascular sealant products.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Baxter's BioSurgery division offers TISSEEL fibrin sealant and FLOSEAL hemostatic matrix, the most directly comparable surgical sealant franchise to TISSIUM's SETALIUM and COAPTIUM lines. Baxter competes in the same surgical closure and tissue reconstruction categories across similar hospital customers.

TypeBroad incumbent
Description

Ethicon offers EVICEL fibrin sealant and SURGIFLO hemostatic matrix as part of a broad surgical portfolio. While much larger than TISSIUM, Ethicon competes directly in the surgical sealant/adhesive category and serves the same hospital and surgical center customers.

TypeDirect peer
Description

Artivion (formerly CryoLife) markets BioGlue, a surgical adhesive used in cardiovascular and reconstructive surgery. Artivion is a focused direct competitor in synthetic surgical adhesives for vascular and tissue reconstruction, overlapping with TISSIUM's SETALIUM vascular sealant.

TypeBroad incumbent
Description

Medtronic's Surgical Innovations division offers hemostatic and sealant products as part of a broad surgical portfolio. While Medtronic's surgical sealants are not its primary focus, it competes for the same hospital purchasing relationships and surgical closure budgets.

TypeBroad incumbent
Description

BD offers surgical hemostasis products including the Avitene family of collagen-based hemostats and other adjunctive hemostatic agents. BD competes in surgical tissue sealing through its broad medical device portfolio targeting the same hospital and surgical center customers.

TypeDirect peer
Description

Advanced Medical Solutions is a UK-based specialty medtech focused on tissue adhesives (LiquiBand) and collagen-based sealants (RESORBA). AMS is a directly comparable mid-sized peer in the surgical sealants and adhesives market with overlapping indications in wound closure.

TypeDirect peer
Description

Integra LifeSciences offers DuraGen and other surgical sealant products for neurosurgery and tissue reconstruction. Integra competes in adjacent specialty surgical closure markets and is similar in scale to TISSIUM with a comparable specialty surgical focus.

TypeBroad incumbent
Description

Stryker acquired Cohera Medical (maker of Sylys surgical sealant) and operates a broad surgical equipment portfolio. Stryker competes broadly in surgical devices and now directly in surgical sealants through Cohera's assets.

TypeEmerging player
Description

Arch Therapeutics develops AC5, a self-assembling peptide hemostatic agent for surgical and wound care applications. Arch is an emerging, smaller competitor focused on a specific niche within surgical sealants and hemostats, partially overlapping with TISSIUM's platform.

TypeBroad incumbent
Description

Smith+Nephew offers advanced wound management and surgical products including tissue adhesives for wound closure. While broader than TISSIUM, Smith+Nephew serves overlapping surgical and wound care end markets with established commercial infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TISSIUM

Surgical Medical Devicestissium.com

TISSIUM is a Paris-based medtech company developing proprietary light-activated biomorphic programmable polymers for tissue reconstruction, commercializing the FDA-authorized COAPTIUM CONNECT sutureless nerve repair system to hospitals and surgical centers while building a pipeline across hernia and cardiovascular indications.

What TISSIUM does

TISSIUM (formerly Gecko Biomedical) is a Paris-headquartered, privately-held medtech company founded in 2013 that develops proprietary biomorphic programmable polymers for tissue reconstruction. The company's core technology is a family of fully biosynthetic, light-activated polymers that conform to and integrate with surrounding tissue and whose building blocks can be tuned to match tissue-specific mechanical and biological requirements; these polymers are deployed alongside 3D-printed bioresorbable chambers using proprietary digital light projection manufacturing techniques. The IP base derives from research at MIT and Brigham and Women's Hospital, and is protected by 26 patent families encompassing 88 granted patents.

TISSIUM monetizes its platform through the sale of medical devices to hospitals and surgical centers, with its first commercial product, COAPTIUM CONNECT — a sutureless peripheral nerve repair system — receiving FDA De Novo authorization in June 2025 and entering U.S. direct sales in July 2025. The company pursues an enterprise field-sales motion targeting surgical specialties, and is investing in additional pipeline indications including atraumatic hernia mesh fixation (first patients treated September 2023) and a CE-Marked vascular sealant (SETALIUM). TISSIUM operates a manufacturing facility in Roncq, France, a U.S. commercial office in Cambridge, Massachusetts, and is led by co-founder-CEO Christophe Bancel alongside co-founder Maria Pereira (Deputy CEO and CIO), with scientific co-founders Robert Langer (MIT) and Jeffrey M. Karp (Brigham and Women's Hospital) anchoring the research and clinical agenda.

The business has been funded through approximately €170 million of cumulative equity, debt, and non-dilutive capital from investors including Sofinnova Partners, Cathay Health, Omnes Capital, Bpifrance, the European Investment Bank, and others, including a €60 million package in 2025-2026 (a €30M Series D2 round plus a €30M EIB facility) earmarked for U.S. commercial launch and pipeline advancement. Revenue figures are not publicly disclosed, and the company is effectively at the very start of its commercial ramp following U.S. market entry.

TISSIUM firmographics

Firmographics
Name
TISSIUM
Legal name
Tissium SA
Website
https://tissium.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
TISSIUM is a Paris-based medtech company developing proprietary light-activated biomorphic programmable polymers for tissue reconstruction, commercializing the FDA-authorized COAPTIUM CONNECT sutureless nerve repair system to hospitals and surgical centers while building a pipeline across hernia and cardiovascular indications.
Ownership category
akta.pro rank

TISSIUM industry classification

Industry
Product category
Surgical Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Biomorphic programmable polymers
  • Surgical sealants adhesives
  • Sutureless nerve repair
  • Tissue reconstruction devices
  • Minimally invasive surgery

Where TISSIUM is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices3 records

Markets served

TISSIUM business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Medical Device Sales: Sale of medical devices for tissue reconstruction including COAPTIUM CONNECT nerve repair products and pipeline products for hernia repair and cardiovascular sealing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

TISSIUM product offering

Product offering

Core offering

TISSIUM develops and manufactures proprietary biomorphic programmable polymers used as surgical sealants and adhesives for tissue reconstruction in open and minimally invasive procedures. Its lead commercial product, COAPTIUM® CONNECT, is an FDA-authorized sutureless peripheral nerve repair system that combines a light-activated polymer with a bioresorbable 3D-printed biopolymer chamber to coapt severed nerve endings without sutures. The polymer platform is also being applied to pipeline products for atraumatic hernia mesh fixation and vascular sealing.

Product overview

TISSIUM offers a biopolymer platform with multiple product lines. The core platform consists of proprietary biomorphic programmable polymers that conform to and integrate with surrounding tissue. The flagship commercial product is COAPTIUM® CONNECT, the first FDA-authorized sutureless nerve repair system. The product portfolio includes COAPTIUM® Nerve Products for peripheral nerve repair, hernia repair products using atraumatic fixation technology, and cardiovascular sealant products including SETALIUM™ Vascular Sealant. The platform supports multiple therapeutic areas (peripheral nerve, cardiovascular, gastrointestinal) with delivery and activation devices for enhanced performance.

Differentiator

Problem solved

Functional benefit

Brands

  • COAPTIUM CONNECT: FDA-authorized sutureless peripheral nerve repair system using biomorphic programmable polymers
  • COAPTIUM Nerve Products
  • SETALIUM Vascular Sealant

Products and services

  • COAPTIUM® CONNECT First and only FDA-authorized system for atraumatic sutureless nerve coaptation, using a light-activated surgical polymer within a bioresorbable 3D-printed biopolymer chamber to join severed peripheral nerve endings without sutures. Commercially available in the United States and intended for hospitals and surgical centers performing peripheral nerve repair.
  • COAPTIUM® Nerve Products Product line for peripheral nerve repair, including the COAPTIUM® CONNECT sutureless nerve coaptation system and 3D-printed biopolymer nerve chambers used in atraumatic nerve repair procedures. Targeted at hand, peripheral nerve, plastic, and trauma surgeons in hospitals and surgical centers.
  • SETALIUM™ Vascular Sealant Sterile, biodegradable, bioresorbable sealant in a pre-filled syringe for vascular reconstruction and hemostasis during peripheral vascular surgery. CE Marked for the European market and under FDA IDE in the United States; intended as a complement to sutures for effective surgical closure and prevention of post-operative bleeding.

Quantifiable outcome

  • Enhanced reinnervation and increased muscle weight in animal studies with sutureless nerve repair system
  • +1 more outcomes

Companies that use TISSIUM

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

TISSIUM technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TISSIUM partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • NYU LangoneminorStrategic or Co-development Partner · 24 September 2021Clinical collaboration with surgeons from NYU Langone for research on sutureless nerve repair system.
  • Brigham & Women's HospitalcoreStrategic or Co-development Partner · 24 September 2021Co-founder Robert Langer and Jeffrey Karp from Brigham & Women's Hospital; ongoing clinical collaboration on nerve repair research.
  • SUNY Downstate Medical CenterminorStrategic or Co-development Partner · 24 September 2021Collaboration with surgeons from SUNY Downstate for research on sutureless nerve repair.
  • TÜV SÜDcoreOthers · 2 April 2020Designated notified body under European MDR that provided ISO 13485:2016 compliance certification and CE mark for vascular sealant products.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

TISSIUM competitors and assessment

Company assessment

Direct peers

  • Baxter International: Baxter's BioSurgery division offers TISSEEL fibrin sealant and FLOSEAL hemostatic matrix, the most directly comparable surgical sealant franchise to TISSIUM's SETALIUM and COAPTIUM lines. Baxter competes in the same surgical closure and tissue reconstruction categories across similar hospital customers.
  • Artivion: Artivion (formerly CryoLife) markets BioGlue, a surgical adhesive used in cardiovascular and reconstructive surgery. Artivion is a focused direct competitor in synthetic surgical adhesives for vascular and tissue reconstruction, overlapping with TISSIUM's SETALIUM vascular sealant.
  • Advanced Medical Solutions: Advanced Medical Solutions is a UK-based specialty medtech focused on tissue adhesives (LiquiBand) and collagen-based sealants (RESORBA). AMS is a directly comparable mid-sized peer in the surgical sealants and adhesives market with overlapping indications in wound closure.
  • Integra LifeSciences: Integra LifeSciences offers DuraGen and other surgical sealant products for neurosurgery and tissue reconstruction. Integra competes in adjacent specialty surgical closure markets and is similar in scale to TISSIUM with a comparable specialty surgical focus.

Broad incumbents

  • Johnson & Johnson (Ethicon): Ethicon offers EVICEL fibrin sealant and SURGIFLO hemostatic matrix as part of a broad surgical portfolio. While much larger than TISSIUM, Ethicon competes directly in the surgical sealant/adhesive category and serves the same hospital and surgical center customers.
  • Medtronic: Medtronic's Surgical Innovations division offers hemostatic and sealant products as part of a broad surgical portfolio. While Medtronic's surgical sealants are not its primary focus, it competes for the same hospital purchasing relationships and surgical closure budgets.
  • Becton Dickinson (BD): BD offers surgical hemostasis products including the Avitene family of collagen-based hemostats and other adjunctive hemostatic agents. BD competes in surgical tissue sealing through its broad medical device portfolio targeting the same hospital and surgical center customers.
  • Stryker: Stryker acquired Cohera Medical (maker of Sylys surgical sealant) and operates a broad surgical equipment portfolio. Stryker competes broadly in surgical devices and now directly in surgical sealants through Cohera's assets.
  • Smith+Nephew: Smith+Nephew offers advanced wound management and surgical products including tissue adhesives for wound closure. While broader than TISSIUM, Smith+Nephew serves overlapping surgical and wound care end markets with established commercial infrastructure.

Emerging players

  • Arch Therapeutics: Arch Therapeutics develops AC5, a self-assembling peptide hemostatic agent for surgical and wound care applications. Arch is an emerging, smaller competitor focused on a specific niche within surgical sealants and hemostats, partially overlapping with TISSIUM's platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

TISSIUM social profiles

Digital presence

TISSIUM compliance and trust

Trust signal

Compliance4 records

TISSIUM financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TISSIUM leadership team

Management profile

Number of profiles

Profiles16 records

TISSIUM funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TISSIUM M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TISSIUM

What does TISSIUM do?

TISSIUM develops and manufactures proprietary biomorphic programmable polymers used as surgical sealants and adhesives for tissue reconstruction in open and minimally invasive procedures. Its lead commercial product, COAPTIUM® CONNECT, is an FDA-authorized sutureless peripheral nerve repair system that combines a light-activated polymer with a bioresorbable 3D-printed biopolymer chamber to coapt severed nerve endings without sutures. The polymer platform is also being applied to pipeline products for atraumatic hernia mesh fixation and vascular sealing.

Is TISSIUM a public or private company?

TISSIUM is a private company. It is classified as venture growth investor backed and is currently operating.

When was TISSIUM founded?

TISSIUM was founded in 2013. It employs 101 to 250 people.

Where is TISSIUM based?

TISSIUM is headquartered in Paris, France, in the Europe region.

How does TISSIUM make money?

One revenue line is on record: medical Device Sales.

Who are TISSIUM's main competitors?

Direct peers on record are Baxter International, Artivion, Advanced Medical Solutions and Integra LifeSciences. Broad incumbents are Johnson & Johnson (Ethicon), Medtronic, Becton Dickinson (BD), Stryker and Smith+Nephew. Arch Therapeutics is listed as an emerging player.

Does TISSIUM have an API?

No public API is recorded for TISSIUM.

What industry is TISSIUM in?

TISSIUM's product category is Surgical Medical Devices. Its primary akta.pro industry code is HLAHAFAH, Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageTISSIUM® Receives CE Mark for ECLIPSIUM®, Its Atraumatic Hernia Repair SolutionTISSIUM received CE marking for ECLIPSIUM, its atraumatic mesh fixation solution for ventral hernia repair. The approval follows the European ALPHA clinical study and enables European commercialization, with an initial release expected in 2027. The company is also advancing U.S. clinical development.GlobeNewswireTISSIUM® Receives CE Mark for ECLIPSIUM®, Its Atraumatic Hernia Repair SolutionTISSIUM received CE marking for ECLIPSIUM, its atraumatic mesh fixation solution for ventral hernia repair, enabling European commercialization. The approval follows the U.S. FDA De Novo authorization of COAPTIUM CONNECT, and ECLIPSIUM is expected to launch in Europe in 2027.GlobeNewswireTISSIUM® obtient le marquage CE pour ECLIPSIUM®, sa solution de réparation atraumatique des herniesTISSIUM received CE marking for ECLIPSIUM, its atraumatic hernia repair device, enabling European commercialization. The device follows FDA approval of COAPTIUM CONNECT for nerve repair. Commercial launch in Europe is planned for 2027, with US development ongoing.Pulse 2.0TISSIUM Secures €60 Million Financing Package To Support Commercial And Clinical ActivitiesTISSIUM announced a €60 million financing package combining a completed €30 million Series D2 round and a €30 million facility from the European Investment Bank to support its commercial and clinical activities. The financing follows FDA marketing authorization of COAPTIUM CONNECT and the company's entry into the U.S. commercial market. The funding is expected to accelerate commercial execution and pipeline development as TISSIUM transitions into a commercial-stage medtech company.FinSMEsTissium Raises €60M in Equity and Debt FinancingTissium, a Paris-based biomorphic polymer developer, raised €60M in equity and debt financing. The package includes a €30M Series D2 equity round and a €30M EIB venture debt facility. Funds will support the US commercial rollout of its FDA-authorized COAPTIUM CONNECT system and advance clinical pipelines.Medical BuyerTISSIUM secures €60M in fundsTISSIUM announced a €60 million financing package, combining a €30 million Series D2 round completed at the end of 2025 with a €30 million venture debt facility from the European Investment Bank. The financing follows the FDA marketing authorization and US commercial launch of COAPTIUM® CONNECT, the company's first commercial product, and supports continued pipeline development across atraumatic nerve repair, hernia repair, and cardiovascular applications. TISSIUM expects to draw the first €10 million tranche of the EIB facility before the end of June 2026, providing capital for US commercial execution and platform expansion.Pulse 2.0TISSIUM Secures €60 Million To Support Commercial And Clinical ExpansionTISSIUM announced a €60 million financing package, consisting of a completed €30 million Series D2 round and a €30 million financing facility from the European Investment Bank, to support commercial and clinical expansion. The funding follows FDA marketing authorization for COAPTIUM CONNECT, the company's first commercial product, enabling its entry into the U.S. market. The financing will also advance pipeline development across atraumatic nerve repair, hernia repair, and cardiovascular applications, with the first €10 million EIB tranche expected before June 2026.citybizTissium Secures $68M for US Launch of Sutureless Nerve Repair SystemParis- and Boston-based medtech company Tissium has secured approximately €60 million ($68.1 million) through a completed Series D2 round and an additional €30 million financing facility from the European Investment Bank to support U.S. market expansion and product development. The funding will specifically support the U.S. commercial launch of Coaptium Connect, Tissium's FDA-authorized sutureless peripheral nerve repair system, with the first EIB tranche expected by month-end. Founded in 2013 and operating from Paris and Cambridge, Massachusetts, the company is transitioning from development-stage to commercial operations with six additional products in its pipeline.MobiHealthNewsTISSIUM secures $68 million to expand tissue reconstruction platformTISSIUM, a medtech company developing programmable polymers for tissue reconstruction, announced a €60 million ($68.1 million) financing package consisting of a completed Series D2 round and an up-to-€30 million facility from the European Investment Bank. The funding will support the U.S. commercial launch of COAPTIUM CONNECT, the company's FDA-authorized sutureless nerve repair product, as well as clinical programs in hernia repair and cardiovascular applications. The financing marks TISSIUM's transition into a commercial-stage medtech company following its first product authorization.